Daily programme - 10 June 2026

Wednesday 10 June 2026

Time Session
08:30
09:15
This interactive session explores collaboration between industry and academia, offering practical perspectives from industry experts. Each expert will deliver a 5-minute introduction, sharing their experience, role, and insights into working across sectors. A moderator will guide the discussion with follow-up questions to deepen the conversation and surface actionable takeaways. The session then opens to the audience for an open “Ask Me Anything” Q&A, encouraging questions and active participation. Designed as a fully interactive format, the session features no slides or screens, prioritizing dialogue and direct engagement.
AndreasTrumpp Moderator HI-STEM GmbH in the German Cancer Research CenterGermany
Career Development Area
sponsored Industry Symposium
Room F1+2+3
TP53 mutations are common in AML, often as “multi-hit” types linked to complex karyotypes. Using single-cell DNA sequencing and phenotypic analysis, we examined the zygosity and clonal architecture of TP53m AML. Among eight patients, “multi-hit” TP53 anomalies appeared in blast cells but not in mature lymphoid populations. Minor TP53m heterozygous clones persisted in mature cells and at remission, with dominant “multi-hit” clones resurfacing at relapse. The combined scDNAseq and CITEseq approach highlights distinct mutation patterns, aiding therapy guidance by distinguishing pathological multi-hit mutations from clonal haematopoiesis at remission.
JenniferStobbs Industry Moderator/ Chair Mission BioUnited Kingdom
  • 08:30
    Introduction
    JenniferStobbs Industry Speaker Mission BioUnited Kingdom
  • 08:35
    Discover Multiomics Insights at Single-Cell Resolution with Tapestri from Mission Bio
    MehdiBenSassi Industry Speaker Mission BioFrance
  • 08:45
    Single-cell DNA sequencing analysis with Tapestri® unveils the intricate clonal architecture of TP53-mutated acute myeloid leukemia.
    SylvainGarciaz Industry Speaker Institut Paoli-CalmettesFrance
Room F6+7+8
09:20
10:55
JukkaWestermarck Co-Chair University of TurkuFinland
MariangelaRusso Co-Chair University of TorinoItaly
  • 09:20
    Mechanistic insights into the consequences of chromosome segregation errors on genome integrity
    StefanoSantaguida Speaker Santaguida Lab, University of MilanItaly
  • 09:45
    Proffered Paper: Selected from Abstracts - to be announced in 2026
  • 09:55
    How environmental exposures and DNA repair shape cancer mutational signatures
    SheeraAdar Speaker The Adar LabIsrael
  • 10:20
    Proffered Paper: Selected from Abstracts - to be announced in 2026
  • 10:30
    Aneuploidy as an engine of tumor evolution
    UriBen-David Speaker Tel Aviv UniversityIsrael
Room F1+2+3
  • 09:20
    Targeting the pro-tumorigenic effects of TGFb in tumor treatment
    Carl-HenrikHeldin Speaker Uppsala UniversitySweden
  • 09:45
    Proffered Paper: Selected from Abstracts - to be announced in 2026
  • 09:55
    The role of neurons in carcinomas
    AndreasTrumpp Speaker HI-STEM GmbH in the German Cancer Research CenterGermany
  • 10:20
    Proffered Paper: Selected from Abstracts - to be announced in 2026
  • 10:30
    Pulmonary innervation impacts tumour progression: A tale of two cancers
    LeanneLi Speaker The Francis CRICK InstituteUnited Kingdom
Room F6+7+8
Maria M.Caffarel Co-Chair Biogipuzkoa Health Research InstituteSpain
RenatoOstuni Co-Chair IFOM-IEOItaly
  • 09:20
    Molecular and spatial control of immune microenvironments in pancreatic cancer
    RenatoOstuni Speaker IFOM-IEOItaly
  • 09:45
    Proffered Paper: Selected from Abstracts - to be announced in 2026
  • 09:55
    Determinants of B cell function in cancer
    YuliyaPylayeva-Gupta Speaker UNC School of MedicineUnited States
  • 10:20
    Proffered Paper: Selected from Abstracts - to be announced in 2026
  • 10:30
    Triggering innate lymphocytes with real and virtual cues for cancer immunotherapy
    CamillaJandus Speaker Jandus LabSwitzerland
Room P1+2+3
10:30
20:00
Poster Session Wednesday (Poster Viewing)
Poster and Exhibition Hall
10:30
19:00
Exhibition
Poster and Exhibition Hall
10:55
11:35
Coffee Break / Exhibition / Industry Spotlight
Poster and Exhibition Hall
Room P1+2+3
11:10
11:25
Cellecta, Inc. Industry Spotlight Session
Spotlight Theatre
11:35
13:10
Marisol S.Soengas Co-Chair Spanish National Cancer Research Center (CNIO)Spain
  • 11:35
    Decoding host-microbiome interactions in cancer immunity. Killing cancer with a gut instinct
    EvangelosGiampazolias Speaker University of ManchesterUnited Kingdom
  • 12:00
    Proffered Paper: Selected from Abstracts - to be announced in 2026
  • 12:10
    The microbiota in cancer treatment efficacy
    MariaRescigno Speaker CeMMAustria
  • 12:35
    Proffered Paper: Selected from Abstracts - to be announced in 2026
  • 12:45
    Title to be announced
    YifatMerbl Speaker The Merbl LabIsrael
Room F1+2+3
Arkaitz Carracedo Perez Co-Chair CIC bioGUNESpain
MatheusHenriqueDias Co-Chair Princess Máxima CenterNetherlands
  • 11:35
    A Complex TIME: the role of the aging tumor immune microenvironment in tumor progression
    Ashani T.Weeraratna Speaker John Hopkins Bloomberg School of Public HealthUnited States
  • 12:00
    Proffered Paper: Selected from Abstracts - to be announced in 2026
  • 12:10
    Intersection of tumorigenesis and aging-associated decline in lung regenerative potential
    TuomasTammela Speaker The Tuomas Tammela LabUnited States
  • 12:35
    Proffered Paper: Selected from Abstracts - to be announced in 2026
  • 12:45
    Ageing and cancer: mechanistic links
    GuidoKroemer Speaker The Kroemer LabFrance
Room F6+7+8
BeatrizSalvador Co-Chair Cardiff UniversityUnited Kingdom
NuriaLopez-Bigas Co-Chair IRB BarcelonaSpain
  • 11:35
    Using complex models of colorectal cancer to investigate therapeutic targeting
    OwenSansom Speaker School of Cancer SciencesUnited Kingdom
  • 12:00
    Proffered Paper: Selected from Abstracts - to be announced in 2026
  • 12:10
    Evolution of the pancreatic cancer microenvironment from early lesions to invasive disease
    MarinaPasca di Magliano Speaker University of Michigan, Medical SchoolUnited States
  • 12:35
    Proffered Paper: Selected from Abstracts - to be announced in 2026
  • 12:45
    Title to be announced
    PhilJones Speaker Cambridge Stem Cell InstituteUnited Kingdom
Room F9+10
  • 11:35
    Single-cell Phenoscaping of Tumour Microenvironment Organoids
    ChrisTape Speaker University College LondonUnited Kingdom
  • 12:00
    Proffered Paper: Selected from Abstracts - to be announced in 2026
  • 12:10
    From pixels to prognosis: using AI-driven spatial analysis to unlock clinically actionable biomarkers
    AndreasSpitzmüller Speaker AstraZenecaUnited Kingdom
  • 12:35
    Proffered Paper: Selected from Abstracts - to be announced in 2026
  • 12:45
    Towards fast and accessible precision oncology
    EytanRuppin Speaker National Cancer InstituteUnited States
Room P1+2+3
13:15
15:15
Lunch Break / Exhibition / Poster Viewing
Poster and Exhibition Hall
Room P1+2+3
13:30
14:15
Understanding cancer biology through a single molecular lens often leaves critical mechanisms unresolved. Increasingly, researchers are combining complementary molecular layers to build a more comprehensive view of disease—connecting genetic, epigenetic, proteomic, and spatial signals to better understand tumor development, heterogeneity, and progression. This symposium brings together scientists applying integrated multiomic approaches to address complex biological questions in cancer research. By featuring perspectives from researchers at different stages of their scientific careers, the session highlights how connecting diverse molecular signals into a unified analytical view is driving biological discovery and translational investigation. Together, these perspectives illustrate how examining cancer biology from multiple, complementary molecular angles supports a more comprehensive understanding of cancer biology.
  • 13:30
    Opening
  • 13:35
    TBC
    BodourSalhia Industry Speaker Inaugural (Interim) Chair & Associate Professor, Dept of Cancer Biology Keck School of Medicine of USCUnited States
  • 14:00
    Expanding cfDNA whole‑genome analysis with integrated genetic, fragmentomic, and epigenetic signals.
    ArianeHallermayer Industry Speaker Head of Research & Development, Medical Genetics Center (MGZ)Germany
Room F1+2+3
F.Hoffmann - La Roche Industry Symposium
Room F6+7+8
FFPE is the most abundant clinical sample type used in cancer research. However, extracting high-quality genomic, transcriptomic, and proteomic data from FFPE remains a major challenge. This symposium explores robust and reliable sample preparation workflows that transform FFPE from a difficult specimen into a powerful resource for multi-Omics analysis. Experts will highlight AFA enabled workflows that maximize analyte recovery, preserve molecular integrity, and deliver confident results for DNA, RNA, and proteins. Discover how integrated, automation ready workflows can provide deeper insights from FFPE, thereby accelerating biomarker discovery, translational research, and precision oncology.
AkshayDhingra Industry Moderator/ Chair CovarisGermany
  • 13:30
    Introduction
    AkshayDhingra Industry Moderator/ Chair CovarisGermany
  • 13:35
    From FFPE to DNA and RNA: A Comprehensive ride in one plate
    Erik Soderback Industry Speaker CovarisSweden
  • 13:50
    From Tumor Disposition to Metastatic Evolution: AI-powered Pathology Integrated with Functional Analysis and Clinical Metadata Improve Treatment Prediction
    GyorgyMarko-Varga Industry Speaker Lund UniversitySweden
Room F9+10
13:45
15:00
Career Development Session 2A
(open to EACR Early Career & Student Members, pre-registration required)
ElisaOricchio Coordinator ISREC-EPFLSwitzerland
Career Development Area
14:30
15:15
Spatial biology enables detailed analysis of molecular processes within native tissue architecture. Using MACSima® Imaging Cycling Staining (MICS), hundreds of proteins and dozens of RNA markers can be detected on the same section, generating high dimensional datasets that enhance cellular characterization and improve therapeutic target solutions. After an introduction into Miltenyi Biotec's innovative spatial biology and imaging solutions, we will demonstrate how B cells play a pivotal role in shaping the TME and tertiary lymphoid structures (TLS). The functions of specific B cell subsets in cancer pathogenesis remain unclear. Using a tissue-centric single-cell RNA-sequencing pipeline, flow cytometry, and high-plex spatial biology MACSima platform, we identify CD27⁻IgD⁻CD21⁺CD11c⁻ double negative 1 (DN1) B cells as a regulatory population enriched in RCC tumours and associated with worse prognosis. These cells localize within immature tertiary lymphoid structures near IL-10⁺ and TGFβ⁺ CD8⁺ T cells. TLR signalling drives their differentiation, and DN1 B cells suppress CD8⁺ T cell cytotoxicity partially via IL-10 and TGFβ. Our findings reveal a novel immune evasion mechanism with potential diagnostic and therapeutic relevance.
  • 14:30
    Introduction to Miltenyi Biotec’s spatial biology portfolio
    Sara Rahmati Industry Speaker Miltenyi BiotecGermany
  • 14:40
    Tumour-infiltrating CD27-IgD- regulatory B cells suppress cytotoxic CD8+T cell responses in renal cell carcinoma: A multi-modal and spatial biology approach
    Tumour-infiltrating CD27-IgD- regulatory B cells suppress cytotoxic CD8+T cell responses in renal cell carcinoma: A multi-modal and spatial biology approach
    IsabellaWithnell Industry Speaker University College London (UCL), United Kingdom
Room F1+2+3
sponsored Industry Symposium
Room F6+7+8
Olink, part of Thermo Fisher Scientific Industry Symposium: Advancing Cancer Research Beyond the Genome with Plasma Proteomics
Proteomics is reshaping cancer research by providing functional insights that extend beyond the genome. This session highlights how high-throughput plasma protein profiling supports biomarker discovery, patient stratification, and a deeper understanding of cancer biology. Our speakers will present applications spanning early detection, immuno-oncology, and translational research, showcasing the expanding role of proteomics across the cancer research continuum. Together, these examples underline the potential of scalable proteomic approaches to generate more precise, biologically meaningful, and clinically relevant insights in oncology.
Room F9+10
15:20
16:55
JukkaWestermarck Co-Chair University of TurkuFinland
MatheusHenriqueDias Co-Chair Princess Máxima CenterNetherlands
  • 15:20
    Cysteine metabolism in cancer
    PéterNagy Speaker National Institute of OncologyHungary
  • 15:45
    Proffered Paper: Selected from Abstracts - to be announced in 2026
  • 15:55
    The Power of Death: Harnessing Immunogenic Cell Death to Drive Anti-Tumour Immunity
    Pascal Meier Speaker Institute of Cancer ResearchUnited Kingdom
  • 16:20
    Proffered Paper: Selected from Abstracts - to be announced in 2026
  • 16:30
    What doesn't kill you makes you stranger: Checkpoints dictating entry to apoptosis versus senescence
    Seamus J.Martin Speaker Trinity College Dublin, The Martin LabIreland
Room F1+2+3
Marisol S.Soengas Chair Spanish National Cancer Research Center (CNIO)Spain
  • 15:20
    Roles of fibroblast subtypes in pancreatic cancer-associated cachexia
    GiuliaBiffi Speaker Cancer Research UK, Cambridge InstituteUnited Kingdom
  • 15:45
    Proffered Paper: Selected from Abstracts - to be announced in 2026
  • 15:55
    How the microbiome induces genotype:phenotype convergence to drive early onset colorectal cancer
    KarunaGanesh Speaker The Karuna Ganesh Lab / Sloan Kettering InstituteUnited States
  • 16:20
    Proffered Paper: Selected from Abstracts - to be announced in 2026
  • 16:30
    Metabolic reprogramming of fibroblasts in wound healing and cancer
    Sabine Werner Speaker ETH ZurichSwitzerland
Room F6+7+8
ChiaraAmbrogio Chair University of TorinoItaly
  • 15:20
    First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer
    StefanLaufer Speaker University of TuebingenGermany
  • 15:45
    Proffered Paper: Selected from Abstracts - to be announced in 2026
  • 15:55
    Title to be announced
    PatrickBarth Speaker EPFLSwitzerland
  • 16:20
    Proffered Paper: Selected from Abstracts - to be announced in 2026
  • 16:30
    Targeted protein degradation for cancer therapy
    AlessioCiulli Speaker University of Dundee, Ciulli LabUnited Kingdom
Room F9+10
AlbertoBardelli Chair University of Torino / IFOM ETSItaly
  • 15:20
    Integrative analyses of biomarker studies to transform advanced prostate cancer care
    Johannde Bono Speaker The Institute of Cancer Research, Drug Development UnitUnited Kingdom
  • 15:45
    Proffered Paper: Selected from Abstracts - to be announced in 2026
  • 15:55
    Can we modify a cancer diagnosis to improve treatment?
    AlbertoBardelli Speaker University of Torino / IFOM ETSItaly
  • 16:20
    Reading the Molecular Future of Colon Cancer in the Blood
    Silvia Marsoni Speaker Silvia Marsoni LabItaly
  • 16:45
    Questions & Answers
Room P1+2+3
16:55
17:30
Coffee Break / Exhibition / Industry Spotlight
Poster and Exhibition Hall
Room P1+2+3
17:10
17:25
LGC Industry Spotlight Session
Spotlight Theatre
17:30
18:15
Johanna AJoyce Co-Chair Ludwig Institute for Cancer ResearchSwitzerland
YardenaSamuels Co-Chair Weizmann Institute of ScienceIsrael
  • 17:30
    Learnings from RAF inhibitor drug discovery
    Gideon Bollag Speaker Opna BioUSA
  • 17:40
    Resistance to BRAF Inhibition: Consequences and Therapeutic Opportunities
    Darrin Stuart Speaker Antares TherapeuticsUnited States
  • 17:50
    Learning the biology of BRAF mutant cancers from the determinants of therapeutic resistance
    KeithFlaherty Speaker Harvard University, Mass General InstituteUSA
  • 18:00
    Discussion
Room P1+2+3
18:15
18:40
Posters in the Spotlight - Wednesday
Spotlight Theatre
Maria M.Caffarel Moderator Biogipuzkoa Health Research InstituteSpain
Room P1+2+3
18:40
20:00
Poster Discussion Session WEDNESDAY (at Poster Area)
Poster and Exhibition Hall
Room P1+2+3